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Abstract  1 
Background: Schizophrenia is associated with a high economic burden. Economic models can help to inform 2 
resource allocation decisions to maximise benefits to patients. 3 
Objectives: This systematic review aims to assess the availability, quality and consistency of conclusions of 4 
health economic models evaluating the cost-effectiveness of interventions for schizophrenia.  5 
Methods: An electronic search was performed on multiple databases (MEDLINE, EMBASE, PsycInfo, 6 
Cochrane database of systematic reviews, NHS Economic Evaluation Database and Health Technology 7 
Assessment database) to identify economic models of interventions for schizophrenia published between 2005-8 
2020. Two independent reviewers selected studies for inclusion. Study quality was assessed using the National 9 
Institute for Health and Care Excellence (NICE) checklist and the Cooper hierarchy. Model characteristics and 10 
conclusions were descriptively summarised. 11 
Results: Seventy-three models met inclusion criteria. 78% of existing models assessed antipsychotics, however, 12 
due to inconsistent conclusions reported by different studies, no antipsychotic can be considered clearly cost-13 
effective compared with the others. A very limited number of models suggest that the following non-14 
pharmacological interventions might be cost-effective: psychosocial interventions, stratified tests, employment 15 
intervention and intensive intervention to improve liaison between primary and secondary care. The quality of 16 
included models is generally low due to use of a short time horizon, omission of adverse events of interventions, 17 
poor data quality and potential conflicts of interest.  18 
Conclusions: This review highlights a lack of models for non-pharmacological interventions, and limitations of 19 
the existing models, including low quality and inconsistency in conclusions. Recommendations on future 20 




Key Points for Decision Makers 1 
• This is the first systematic review of model-based economic analyses which covers the entire 2 
schizophrenia care pathway, by including any intervention for the prevention, detection, diagnosis, 3 
treatment and follow-up of schizophrenia. 4 
• This review highlights a lack of models for non-pharmacological interventions, and low quality of 5 
existing models. Common reasons for low-quality include use of a time-horizon which is not 6 
sufficiently long, failure to capture the health and cost impact of adverse events of the interventions 7 
under assessment, and potential conflicts of interest. 8 
• Due to inconsistent conclusions reported by different studies, no antipsychotic can be considered 9 
clearly cost-effective compared with the others. A very limited number of models suggest that the 10 
following non-pharmacological interventions might be cost-effective: psychosocial interventions, 11 
stratified tests, employment intervention and intensive intervention to improve liaison between primary 12 
and secondary care. 13 
• A consistent basis for the model structure, use of evidence and assumptions in health economic models 14 
is required in order to improve the consistency and quality of future health economic models in 15 
schizophrenia. This consistent basis could be applied using generic agreed models, which might 16 
include a de novo whole disease model. 17 
 18 
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A systematic review of economic models across the entire schizophrenia pathway 1 
1. Introduction 2 
Schizophrenia is a chronic, severe and disabling psychiatric disorder, or cluster of disorders, characterised by 3 
psychotic symptoms that alter a person’s perceptions, thoughts, affect and behaviour. The schizophrenia clinical 4 
guideline developed by the National Institute for Health and Care Excellence (NICE) recommends a wide range 5 
of interventions for people who are at risk of, or who have a diagnosis of, schizophrenia, including 6 
antipsychotics, cognitive behaviour therapy (CBT), family intervention, peer support, physical health checks 7 
and interventions, and education and employment support [1]. However, the rates of implementation are low for 8 
some recommended interventions including physical health interventions (13%), family interventions (31%), 9 
CBT (41%) and supported employment programmes (63%) [2]. It has been reported that the allocations for 10 
mental health care in national health budgets are commonly disproportionate to the burden of mental health 11 
conditions in many countries [3]. For example, in the UK, although mental disorders are responsible for 28% of 12 
the total burden of disease, mental health care only receives 13% of total NHS funding [4]. As a result, mental 13 
health commissioners may not be in a position to fund all recommended interventions and must decide how to 14 
allocate limited budgets across the entire care pathway in a way that maximises benefits to patients.  15 
 16 
Since clinical trials rarely collect all of the information required to estimate the full profiles of health outcomes 17 
and costs for all interventions relevant to a decision problem, health economic modelling is routinely used to 18 
simulate the current and proposed systems of care, with input data obtained from multiple sources [5]. The 19 
purpose of this review is to conduct a systematic review of existing health economic models of any type for 20 
schizophrenia and provide recommendations for future research. Specific objectives were as follows: 21 
(1) To assess the availability of economic models of interventions for patients who are at risk of, or who 22 
have a diagnosis of schizophrenia; 23 
(2) To critically examine the quality of existing health economic models; 24 
(3) To summarise the conclusions reported by existing health economic models and to assess the 25 
consistency of conclusions.  26 
 27 
2 Methods 28 
This systematic review was conducted according to the PRISMA recommendations for reporting systematic 29 




2.1 Inclusion/exclusion criteria  2 
Inclusion and exclusion criteria were defined a priori. Studies were included if they met all of the following 3 
criteria: (i) studies reporting model-based economic evaluations adopting either a cost-effectiveness analysis 4 
(CEA) or cost-utility analysis (CUA) approach; (ii) focus on young people (under 18 years of age) and/or adults 5 
(18 years and older) who are at clinical high risk of psychosis (CHR), with a non-specific diagnosis of 6 
psychosis, or with a diagnosis of schizophrenia (including schizoaffective disorder and delusional disorder), and 7 
(iii) interventions targeted at the prevention, detection, diagnosis, treatment or follow-up of schizophrenia. No 8 
restrictions by country, health care setting or monetary currency were applied. Studies were excluded if they met 9 
any of the following criteria: (i) reviews, commentaries, letters, editorials, or abstracts; (ii) published before 10 
2005, or (iii) not reported in English.  11 
 12 
2.2 Search strategy 13 
Electronic biomedical and psychological databases searched included MEDLINE (including in-Process & other 14 
non-indexed), EMBASE and PsycINFO, accessed through the Ovid interface (https://ovidsp.ovid.com/). In 15 
addition, the NHS Economic Evaluation Database (NHSEED) and the Health Technology Assessment Database 16 
(HTA) were searched, accessed through the Cochrane library interface 17 
(http://onlinelibrary.wiley.com/cochranelibrary/search8). The search strategies included Medical Subject 18 
Heading (MeSH) terms and text words. Each follows a similar structure: population terms AND economic 19 
evaluation terms AND modelling terms AND limitation terms. The original search, first update search and 20 
second update search were conducted on 22nd June 2015, 4th March 2018, and 21st January 2020), respectively. 21 
The detailed search strategy is reported in Online Resource 1, Section 1. Retrieved search results were 22 
downloaded into Endnote X8.0.2. 23 
 24 
2.3 Assessment of abstracts for inclusion  25 
Screening of abstracts and papers against the inclusion criteria was carried out by two reviewers (HJ and EA for 26 
the original and first update search; HJ and DA for the second update search). Final inclusion of studies in the 27 
review was determined by agreement of both reviewers, with disagreements resolved by discussion. A number 28 
of additional strategies were devised to help ensure that relevant studies were not missed. Firstly, key papers and 29 
the publications of key health economists were checked for inclusion and for additional relevant papers. 30 
7 
 
Secondly, published systematic reviews relevant to the target population were located through a separate search 1 
of NICE clinical guidelines, NICE technology appraisals and National Institute for Health Research (NIHR) 2 
health technology assessment (HTA) reports. The search terms used by the located systematic reviews were 3 
used to inform the development of search strategies for the current systematic review, and the studies included 4 
within those reviews were checked for relevance with respect to the inclusion criteria of the current systematic 5 
review. Finally, the reference lists of all included studies identified via the electronic search were checked for 6 
any additional studies that may have been missed by the electronic search strategies. 7 
 8 
2.4 Data extraction and analysis 9 
Data were extracted by one reviewer (HJ) and checked by a second reviewer (EA for the original and first 10 
update search, DA for the second update search), with disagreements resolved by discussion. The following 11 
information was extracted from all included studies: author; year; country; study objective; type of economic 12 
evaluation; intervention and comparator; modelling method; willingness-to-pay threshold (e.g. per quality-13 
adjusted life year [QALY] gained), conclusions, potential conflicts of interest and information on quality criteria 14 
set out by the NICE checklist and Cooper hierarchy. Study characteristics and conclusions were summarised 15 
descriptively. 16 
 17 
2.5 Quality assessment  18 
Seven commonly used checklists for economic evaluations [7-13] were considered for the current review, they 19 
differ from each other in terms of the aim of the quality assessment (e.g. to assess reporting quality, or 20 
methodological quality of economic evaluations, or both) and the types of studies covered (e.g. trial-based 21 
economic evaluations, model-based economic evaluations, or both). To be of value to the current review, 22 
checklists needed to (i) focus on methodological quality of studies; (2) be appropriate for modelling studies; and 23 
(3) provides an overall judgement regarding the methodological quality of the studies assessed, so to help the 24 
reviewers to summarise and compare the methodological quality of a large number of included studies (e.g. ≥50 25 
studies). Based on these three criteria, two checklists were deemed to be most appropriate for the current review: 26 
Section 2 of the NICE checklist [11] and the Cooper hierarchy [10]. The NICE checklist consists of two 27 
sections. Section 1 aims to assess the applicability of a study to the decision problems that need to be addressed 28 
by the NICE guidance, for example, whether the study population is appropriate to the review question of 29 
interest or whether the system in which the study was conducted is sufficiently similar to the current UK 30 
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context. As the aim of this systematic review was to provide an overview of the availability and quality of all 1 
economic models focusing on the schizophrenia care pathway, Section 1 was not considered relevant. Section 2 2 
of the NICE checklist aims to assess the methodological quality of the study and thus was included. Section 2 3 
consists of twelve quality criteria and an overall assessment. Based on the number and importance of quality 4 
criteria that a study fails, an assessment regarding the overall methodological quality of the study can be 5 
classified into one of the following categories: (i) very serious limitations –the study fails to meet one or more 6 
quality criteria, and this is highly likely to change the conclusions about cost effectiveness, (ii) potentially 7 
serious limitations –the study fails to meet one or more quality criteria, and this could change the conclusions 8 
about cost effectiveness, and  (iii) minor limitations –the study meets all quality criteria, or fails to meet one or 9 
more quality criteria but this is unlikely to change the conclusions about cost effectiveness, potentially serious 10 
limitations and minor limitations. The Cooper hierarchy focuses on the quality of the data sources used to 11 
inform the parameters in a model [10]. The hierarchy provides a list of potential sources for each data 12 
component of interest, including: main clinical effect size, baseline clinical data, adverse events and 13 
complications, resource use, costs and utilities. Sources are ranked on a scale from 1 to 6, with the most 14 
appropriate source assigned a rank of 1. Where multiple data inputs were included within a category (i.e. 15 
adverse events and complications, resource use and cost), the score of the worst sources of evidence were 16 
recorded. Based on the value of the score, the quality of input data was then categorised as high ranked evidence 17 
(score 1-2), medium ranked evidence (score 3-4) or low ranked evidence (score 5-6). The Cochrane Handbook 18 
for Systematic Reviews [14] recommends the Cooper hierarchy as a useful supplement to more comprehensive 19 
checklists such as the NICE checklist.  20 
 21 
3 Results 22 
3.1 Study identification and selection 23 
A total of 1,557 citations were retrieved from electronic searches carried out on three separate occasions 24 
(original search 22nd June 2015; first update d search 4th March 2018, second update search 21st January 2020). 25 
The detailed results of the literature search are reported in Online Resource 1, Section 1. Four modelling studies 26 
known to one of the authors (HJ), but which was not identified by the electronic searches was added to the 27 
database. These four studies were reported in the adult NICE schizophrenia guideline [1], and were missed by 28 
the electronic searches because NICE clinical guidelines are not currently indexed by mainstream electronic 29 
databases. After removing duplicates, 1,250 citations remained: 908 citations identified from the original 30 
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electronic searches, 204 identified from the first updated electronic searches, 134 identified from the second 1 
updated electronic searches, plus the four models identified from the NICE schizophrenia guideline for adults 2 
[1]. Of the 1,250 abstracts reviewed, 981 were excluded for clearly failing to meet at least one inclusion 3 
criterion or meeting at least one exclusion criterion, leaving 269 for full-text review. Of these, 97 were abstracts 4 
only and for the remaining 172, full articles were retrieved. Of these, 77 papers reporting 73 studies (four papers 5 
are corrections of other included studies) satisfied the predefined inclusion criteria and were included in the 6 
review. The inter-reviewer agreement, measured by Cohen's kappa was 0.84, which indicates good agreement. 7 
A modified preferred reporting items for systematic reviews and meta-analyses (PRISMA) diagram [6] for the 8 
literature selection process is provided in Fig. 1. The key data extracted from included studies are reported in the 9 
Online Resource 1, Section 2. 10 
 11 
3.2 Study descriptions  12 
Table 1 summarises the characteristics of included studies. 89.0% of included studies (65/73) were from high-13 
income countries, such as the US (11/73, 15.1%), the UK (11/73, 15.1%) and Sweden (6/73, 8.2%). Fifty-eight 14 
included studies were CUAs (79.5%), while fifteen were CEAs (20.5%). The perspective of cost adopted by 15 
included studies are healthcare system (36/73, 49.3%), third-party payer (22/73, 30.1%), healthcare system and 16 
social care (8/73, 11.0%) and society (7/73, 9.6%). The majority of studies adopted a time horizon from one to 17 
five years (52/73, 71.2%). The most commonly used modelling techniques were Markov model (34/73, 46.6%), 18 
decision tree (24/73, 32.9%) and discrete event simulation (DES) (9/73, 12.3%). In terms of population, the 19 
majority of included studies related to people with a diagnosis of schizophrenia (68/73, 93.2%). The remaining 20 
studies evaluated interventions for people with a non-specific diagnosis of psychosis (5/73, 6.8%) [1, 15-18] and 21 
those at CHR (2/73, 2.7%) [15, 17]. In terms of interventions assessed, most included studies compared the cost-22 
effectiveness of different antipsychotics versus each other, placebo or nothing (57/73, 78.1%). The remaining 23 
studies assessed the cost-effectiveness of different coverage of Medicare drug plans (1/53, 1.6%) [19], 24 
electroconvulsive therapy (ECT) versus antipsychotic (1/53, 1.6%) [20], precision medicine test versus no test 25 
(4/73, 5.5%) [21-24], different monitoring schedules for patients receiving clozapine (1/73, 1.4%) [25], 26 
antipsychotics versus antipsychotics plus psychosocial interventions (5/73, 6.8%) [26-30], CBT versus no CBT 27 
(1/73, 1.4%) [17], improving patients’ access to psychological therapies versus no intervention (1/73, 1.4%) 28 
[18], supported employment programme vs no intervention (1/73, 1.4%) [1], and different modes of liaison 29 
between primary and secondary care services (1/53, 1.6%) [15]. The availability of economic evidence across 30 
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the schizophrenia care pathway is presented in Fig. 2. As shown in Fig. 2, there is high availability of economic 1 
evidence for antipsychotic with or without psychosocial interventions and moderate availability of economic 2 
evidence for prevision medicine test. On the other hand, there is very limited or even no economic evidence 3 
concerning the prevention, case identification, assessment and diagnosis of psychosis and schizophrenia, as well 4 





Table 1 Characteristics of included studies 1 
 Included studies (n=73) 
n (%) 
Country  
High-income countries  65 (89.0) 
Low- and middle-income counties  8 (11.0) 
Type of economic evaluation  
Cost-utility analysis 58 (79.5) 
Cost-effectiveness analysis excluding cost-utility analysis 15 (20.5) 
Perspective of cost  
Healthcare system 36 (49.3) 
Third-party payer 22 (30.1) 
Healthcare system and social care 8 (11.0) 
Society 7 (9.6) 
Time horizon  
<1 year 2 (2.7) 
1-5 year 52 (71.2) 
10-year 6 (8.2) 
Lifetime 13 (17.8) 
Modelling techniques adopted  
Markov model  34 (46.6) 
Decision tree 24 (32.9) 
DES 9 (12.3) 
Microsimulation 5 (6.8) 
Not reported 1 (1.4) 
Target population  
People at clinical high risk of psychosis 21 (2.7) 
People with a non-specific diagnosis of psychosis 51 (6.8) 
People with a diagnosis of schizophrenia 68 (93.2) 
Interventions assessed  
Antipsychotic medication versus each other, placebo or nothing 57 (78.1) 
Different coverage of Medicare drug plans 1 (1.4) 
Electroconvulsive therapy versus antipsychotic medication 1 (1.4) 
12 
 
 Included studies (n=73) 
n (%) 
Precision medicine test versus no test 4 (5.5) 
Different monitoring schedule for patients on clozapine 1 (1.4) 
Antipsychotic medication versus antipsychotic medication plus 
psychosocial interventions 
5 (6.8) 
CBT versus no CBT 1 (1.4) 
Improving patients’ access to psychological therapies 1 (1.4) 
Supported employment programme 1 (1.4) 
Different modes of liaison between primary and secondary care service 1 (1.4) 
Notes: 1 
1: Two studies [15, 17] included two groups of people: people at CHR and people with non-specific diagnosis of psychosis.   2 
 3 
3.3 Quality assessment 4 
The results of the quality assessment are reported below; further detail is provided in Online Resource 1, Section 5 
3.  6 
 7 
3.3.1 NICE checklist 8 
According to the quality assessment results of the NICE checklist, sixty-two studies were deemed to have very 9 
serious limitations (84.9%), eight were deemed to have potentially serious limitations (11.0%), and three were 10 
deemed to have minor limitations (4.1%) [1, 17, 31]. The performance of included studies on all items of the 11 
NICE checklist is shown in Fig. 3. Common problems identified for all included studies are: (1) potential 12 
conflict of interest (58/73, 79.5%); (2) use of time horizon not sufficiently long to reflect all important outcomes 13 
(54/73, 74.0%); and (3) baseline outcome data not obtained from the best available source: (49/73, 67.1%). Of 14 
the sixty-two studies deemed to have very serious limitations, the most common reasons for them to be assessed 15 
as very serious limitations are (some studies can be assessed as very serious limitations for more than one 16 
reasons): (1) did not include all important and relevant costs, for example, the cost of treating adverse events of 17 
antipsychotics (42/62, 67.7%); (2) failure to include all important and relevant outcomes, for example, disutility 18 
caused by adverse events of antipsychotics (40/62, 64.5%); and (3) the model structure did not adequately 19 
reflect the nature of the topic under evaluation (26/62, 41.9%), for example, did not model discontinuation of 20 




3.3.2 Cooper hierarchy 1 
Fig. 4 presents the results of applying the Cooper hierarchy to the included studies. Of the six categories 2 
included in the Cooper hierarchy, three of them (adverse events, resources use and costs) may include multiple 3 
data inputs (i.e. more than one data source can be used for that category). For these three categories, the score of 4 
the lowest quality evidence were reported. As shown in Fig. 4, most studies used high-ranked evidence for unit 5 
costs (49/73, 67.1%) and clinical treatment effects (47/73, 64.4%), and low-ranked evidence for baseline clinical 6 
events (49/73, 67.1%), resource use (47/73, 64.4%) and adverse events (30/73, 41.1%). Of the fifty-eight CUA 7 
studies which modelled patients’ utilities, most used medium-ranked evidence to inform utility estimates (54/58, 8 
93.1%). 9 
 10 
3.4 Results of existing models 11 
The cost-effectiveness conclusions of exiting models are summarised in Table 2. 12 
14 
 
Table 2 Summary of included studies by decision questions assessed 
Target population Number of 
studies 
Countries Study quality Summary of results  Conclusion 
1. Different antipsychotics versus each other, placebo or nothing 
Schizophrenia patients 
in an acute episode 
10 UK (2/10,20.0%) [16, 
32], Czech Republic 






(1/10,10.0%) [37], Spain 
(1/10,10.0%) [38], 
Sweden (1/10,10.0%) 
[39], and US 
(1/10,10.0%) [40] 
Very serious limitations 
(10/10, 100.0%) 
The most cost-effective antipsychotic 
reported by included studies are: 
• Oral paliperidone extended release 
(3/10, 30.0%) [33, 35, 38]; 
• Oral olanzapine (2/10, 20.0%) [34, 
37]; 
• Oral lurasidone (1/10,10.0%) [32]; 
• Oral sertindole (1/10,10.0%) [39]; 
• Oral ziprasidone (1/10,10.0%) [36]; 
• Oral risperidone (1/10,10.0%) [40]; 
• Oral atypical (1/10,10.0%) [16]. 
No antipsychotic can be considered 
clearly cost effective compared with the 
other options. 
Schizophrenia patients 
in remission  
12 US (4/12, 33.3%) [41-
44], Spain (2/12, 16.7%) 
[45, 46], Brazil (1/12, 
8.3%) [47], China (1/12, 




The most cost-effective antipsychotic 
reported by included studies are: 
• Oral olanzapine (3/12, 25.0%) [31, 
41, 43]; 
No antipsychotic can be considered 




Target population Number of 
studies 
Countries Study quality Summary of results  Conclusion 
8.3%) [48], Singapore 
(1/12, 8.3%) [31], 
Thailand (1/12, 8.3%) 
[49], Uganda (1/12, 
8.3%) [50] and UK 
(1/12, 8.3%) [1]. 
25.0%) [41, 42, 49], and 
minor limitations (2/12, 
16.7%) [1, 31]. 
• Oral risperidone (2/12, 16.7%) [47, 
50]; 
• Oral ziprasidone (2/12, 16.7%) [42, 
45]; 
• Oral aripiprazole (1/12, 8.3%) [49]; 
• Olanzapine orally disintegrating 
tablet (1/12, 8.3%) [48]; 
• Oral brexpiprazole (1/12, 8.3%) 
[44]; 
• Oral paliperidone extended release 
(1/12, 8.3%) [46]; 
• Oral zotepine (1/12, 8.3%) [1]. 
General schizophrenia 
patients (psychotic status 
unspecified) 
5 Canada (2/5, 40.0%) 
[51, 52], Australia (1/5, 
20.0%) [53], Germany 
(1/5, 20.0%) [54] and 
Sweden (1/5, 20.0%) 
[55] 
Very serious limitations 
(5/5, 100.0%) [51-55] 
The most cost-effective antipsychotic 
reported by included studies are: 
• Oral aripiprazole (1/5, 20.0%) [55]; 
• Oral asenapine (1/5, 20.0%) [51]; 
• Oral branded risperidone (1/5, 
20.0%) [54]; 
• Oral risperidone (1/5, 20.0%) [52]; 
No antipsychotic can be considered 




Target population Number of 
studies 
Countries Study quality Summary of results  Conclusion 
• Low-dose oral typical (1/5, 20.0%) 
[53]. 
Schizophrenia patients 
who have history of non-
adherence 
24 Finland (2/24, 8.3%) 
[56, 57], Germany (2/24, 
8.3%) [58, 59], Portugal 
(2/24, 8.3%) [60, 61], 
Sweden (2/24, 8.3%) 
[62, 63], US (2/24, 
8.3%) [64, 65], Belgium 
(1/24, 4.2%) [66], 
Canada (1/24, 4.2%) 
[67], China (1/24, 4.2%) 
[68], Croatia (1/24, 
4.2%) [69], Czech 
Republic (1/24, 4.2%) 
[70], France (1/24, 
4.2%) [71], Greece 
(1/24, 4.2%) [72], 
Netherlands (1/24, 
Very serious limitations 
(23/24, 95.8%) and 
potentially serious 
limitations (1/24, 4.2%) 
[78] 
The most cost-effective antipsychotic 
reported by included studies are: 
• Paliperdione LAI (11/24, 45.8%) 
[56, 57, 60, 62, 69-74, 79]; 
• Risperidone LAI (7/24, 29.2%) [58, 
61, 63, 66-68, 77]; 
• Aripiprazole LAI (2/24, 8.3%) [64, 
78]; 
• Olanzapine LAI (2/24, 8.3%) [65, 
76]; 
• Oral atypical (1/24, 4.2%) [59]; 
• Oral olanzapine (1/24, 4.2%) [75]. 
No antipsychotic can be considered 




Target population Number of 
studies 
Countries Study quality Summary of results  Conclusion 
4.2%) [73], Norway 
(1/24, 4.2%) [74], 
Slovenia (1/24, 4.2%) 
[75], Spain (1/24, 4.2%) 
[76], Taiwan (1/24, 
4.2%) [77], UK (1/24, 
4.2%) [78], and United 





3 Australia (1/3, 33.3%) 
[53], South Korea (1/3, 
33.3%) [80] and UK 
(1/3, 33.3%) [20] 
Very serious limitations 
(2/3, 66.7%) [53, 80] 
and potentially serious 
limitations (1/3, 33.3%) 
[20] 
The Australian study [53] compared oral 
clozapine typical antipsychotics for people 
with TRS and found the incremental cost-
effectiveness ratio (ICER) of clozapine 
ranges from $3,000 to 42,000 per DALY, 
which is below the willingness-to-pay (WTP) 
threshold set by the authors ($50,000 per 
DALY). The South Korea study [80] assessed 
four oral antipsychotics: olanzapine, 
risperidone, sertindole and quetiapine, and 
For patients with TRS, clozapine is more 
cost-effective compared to typical 
antipsychotics. However, the relative 
cost-effectiveness between clozapine 
and other atypical antipsychotics (e.g. 
risperidone) is unknown. Therefore, it is 




Target population Number of 
studies 
Countries Study quality Summary of results  Conclusion 
found that risperidone dominates the other 
three antipsychotics. The UK study [20] 
showed that clozapine dominates both 
electroconvulsive therapy (ECT) and 
chlorpromazine/ haloperidol strategy. 
Schizophrenia patients 
who are experiencing 
adverse events of typicals 
1 Australia (1/1, 100.0%) 
[53] 
Very serious limitations 
(1/1, 100.0%) [53] 
The most cost-effective antipsychotic 
reported by the Australian study [53] is oral 
risperidone (1/1, 100.0%) . 
For schizophrenia patients who are 
experiencing adverse events of typical 
antipsychotics, oral risperidone is more 
cost-effective compared to oral 
olanzapine or oral typical antipsychotics.  
Patients with negative 
symptoms of 
schizophrenia 
1 Hungary (1/1, 100.0%) 
[81] 
Very serious limitations 
(1/1, 100.0%) [81] 
The Hungarian study [81] reported that the 
ICER of oral cariprazine is€28,897 per 
QALY compared to oral risperidone, which is 
below the WTP threshold set by the authors 
(€34,764 per QALY) 
For patients with negative symptoms of 
schizophrenia, oral cariprazine is more 
cost-effective than oral risperidone. 
2. Different coverage of Medicare drug plans 
General patient with 
schizophrenia  
1 US (1/1, 100.0%) [19] Very serious limitations 
(1/1, 100.0%) [19] 
The US study [19] compared two strategies: 
(1) ‘Generic-only coverage’ (Medicare covers 
cost for generic antipsychotics); (2) ‘No 
It is cost-effective for Medicare to cover 
cost of generic antipsychotics for general 
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Target population Number of 
studies 
Countries Study quality Summary of results  Conclusion 
coverage’ (Medicare does not cover cost of 
antipsychotic). This study found that 
‘generic-only coverage’ dominates ‘no gap 
coverage’.  
schizophrenia patients, compared to no 
coverage.  
3. Electroconvulsive therapy (ECT) versus antipsychotic 
Patients with TRS  1 UK (1/1, 100.0%) [20] Potentially serious 
limitations (1/1, 
100.0%) [20] 
The UK study [20] showed that for patients 
with TRS who respond to, and can tolerate 
clozapine, clozapine dominates ECT and 
chlorpromazine/ haloperidol strategy. For 
patients with TRS who do not respond to, or 
who cannot tolerate clozapine, ECT 
dominates chlorpromazine/ haloperidol 
strategy.  
For adult patients with TRS who 
respond to, and who can tolerate 
clozapine, clozapine is more cost-
effective compared to ECT and typical 
antipsychotics.  
For adult patients with TRS who do not 
respond to, or who cannot tolerate 
clozapine, ECT is the more cost-
effective compared to typical 
antipsychotics.  
4. Precision medicine test versus no test  
Stable patients with 
schizophrenia who failed 
a first-line antipsychotic 
1 UK (1/1, 100.0%) [23] Potentially serious 
limitations (1/1, 
100.0%) [23] 
The UK study [23] found that use of a  
stratified medicine algorithm with a stratifier 
with 60% sensitivity and specificity in 
For stable patients with schizophrenia 
who failed a first-line antipsychotic, use 
of a stratified test with 60% sensitivity 
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Target population Number of 
studies 
Countries Study quality Summary of results  Conclusion 
identifying patients who respond to a 2nd line 
non-clozapine antipsychotic dominates  
treatment as usual (no stratified test). 
and specificity in identifying patients 
who respond to a 2nd line non-clozapine 
antipsychotic is more cost-effective than 
no test.  
Schizophrenia patients 
in an acute psychotic 
episode 
1 US (1/1, 100.0%) [21] Very serious limitations 
(1/1, 100.0%) [21] 
The US study [21] compared three strategies: 
(1) no test, use clozapine as the first-line 
treatment; (2) no test, use clozapine as the 
third-line treatment; (3) use test (sensitivity 
96%, specificity 38%), use clozapine for 
patients with positive results. The results 
showed that Strategy 3 (use test) was 
dominated by Strategy 1 (no test, clozapine 
first-line treatment). Compared to Strategy 2 
(no test, clozapine first-line treatment), the 
ICER of Strategy 1 is $47,705 per QALY. 
For schizophrenia patients, a stratified 
test with 96% sensitivity and 38% 
specificity for identifying clozapine 
responders may not be cost-effective 
compared to no test.  
Patients with first 
episode psychosis (FEP)  
1 UK (1/1, 100.0%) [22]  
  
Very serious limitations 
(1/1, 100.0%) [22] 
The UK study [22] compared two strategies 
of dosing risperidone: (1) ‘traditional dosing’ 
(all patients receiving the same dose); (2) 
‘patient stratification’ (dosing is 
For patients with FEP who require 
risperidone, it is cost-effective to use a 
stratified test with 100% accuracy to 
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Target population Number of 
studies 
Countries Study quality Summary of results  Conclusion 
individualised for each patient based on the 
results of a test assuming 100% accuracy). 
This study found that the ICER of ‘patient 
stratification’ is £19,252 per QALY.  
inform the starting dose compared to no 
test.  
Adult patients with TRS 
who were taking 
clozapine 
1 US (1/1, 100.0%) [24] Very serious limitations 
(1/1, 100.0%) [24] 
This US study [24] compared three strategies: 
(1) current US absolute neutrophil count 
monitoring (ANCM) schemes; (2) human 
leukocyte antigen (HLA) genotyping 
followed by clozapine, with ANCM only for 
patients who tested positive for one or both 
alleles (genotype-guided blood sampling); (3) 
HLA genotyping followed by clozapine for 
low-risk patients and alternative 
antipsychotics for patients who tested positive 
(clozapine substitution scheme). This study 
found that Strategy 3 was dominated. 
Compared to Strategy 2, the ICER of Strategy 
1 is $3.93 million per QALY, which is above 
For adult patients with TRS who were 
taking clozapine, the most cost-effective 
strategy is to use HLA genotyping 
followed by clozapine, with ANCM only 
for patients who tested positive for one 
or both alleles. 
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Target population Number of 
studies 
Countries Study quality Summary of results  Conclusion 
the WTP threshold set by the authors (US 
dollars $50,000 per QALY). 
5. Different monitoring schedules for patients on clozapine 
Patients with TRS on 
clozapine 
1 Switzerland (1/1, 
100.0%) [25] 
Very serious limitations 
(1/1, 100.0%) [25] 
The Swedish study [25] compared four 
strategies for monitoring white blood cell 
count with no monitoring, and found that the 
ICERs of all four monitoring strategies were 
at least US$970,000 per QALY. 
For patients with TRS on clozapine, no 
monitoring is more cost-effective 
strategy compared to monitoring.  
6. Antipsychotic versus antipsychotic plus psychosocial interventions 
All schizophrenia 
patients  
5 Chile, Nigeria and Sri 
Lanka (1/5, 20.0%) [30], 
Vietnam (1/5, 20.0%) 
[26], Spain (1/5, 20.0%)  
[27], Sub-Saharan 
Africa and South East 
Asia countries (1/5, 
20.0%) [29], and 
Thailand (1/5, 20.0%) 
[28]. 
Very serious limitations 
(5/5, 100.0%) [26-30] 
Of these three studies, the Vitamin [26] and 
the Spanish study [27] found that 
antipsychotics plus psychosocial intervention 
dominates antipsychotics alone, while the 
Thailand study [28] found that compared to 
antipsychotics alone, use of antipsychotics 
plus psychosocial intervention results in an 
ICER of 1,900 baht per DALY, which is 
below the WTP threshold set by the authors 
(110,000 baht per DALY). The two studies 
For general schizophrenia patients, 
antipsychotic plus psychosocial 




Target population Number of 
studies 
Countries Study quality Summary of results  Conclusion 
conducted in Chile, Nigeria and Sri Lanka 
[30] and Sub-Saharan Africa and South East 
Asia countries (1/5, 20.0%) [29] compared 
the current situation with typical 
antipsychotic drug alone, atypical 
antipsychotic drug alone, typical 
antipsychotic drug with psychosocial 
treatment and atypical antipsychotic drug 
with psychosocial treatment. Both studies 
found typical antipsychotic drug with 
psychosocial treatment to be most cost-
effective at a WTP threshold of International 
dollars $2,000 per DALY averted. 
7. CBT versus no CBT 
Patients with ultra-high 
risk of developing 
psychosis or with FEP 
1 Netherland (1/1, 
100.0%) [17] 
Minor limitations (1/1, 
100.0%) [17] 
The Netherlandish study [17] reported that 
care as usual plus CBT dominates care as 
usual.  
For patients with ultra-high risk of 
developing psychosis or with FEP, care 
as usual plus CBT is more cost-effective 
than care as usual. 
8. Improving access to psychological therapies 
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Target population Number of 
studies 
Countries Study quality Summary of results  Conclusion 
Patients with psychosis or 
bipolar disorder 
1 UK (1/1, 100.0%) [18] Very serious limitations 
(1/1, 100.0%) [18] 
The UK study [18] found that compared to 
the current practice, use of the Improving 
Access to Psychological Therapies 
Programme resulted in an ICER of £12.9 per 
WSAS (Work and Social Adjustment Scale) 
point. 
For patients with psychosis or 
bipolar disorder, improving their access 
to psychological therapies may be cost-
effective compared to current practice.  
9. Employment intervention 
Adults with psychosis and 
schizophrenia actively 
seeking employment 
1 UK (1/1, 100.0%) [1] Potentially serious 
limitations (1/1, 
100.0%) [1] 
The UK study [1] found that compared to 
treatment as usual, use of the supported 
employment programme is associated with an 
ICER of £5,723 per QALY, which is below 
the WTP threshold set by the authors 
(£20,000-30,000 per QALY). 
For adults with psychosis and 
schizophrenia actively seeking 
employment, supported employment 
programme is more cost-effective 
compared to treatment as usual.  
10. Different modes of liaison between primary and secondary care service 
People with possible 
psychotic symptoms   
1 UK (1/1, 100.0%) [15] Potentially serious 
limitations (1/1, 
100.0%) [15] 
The UK study [15] compared different 
intensity of liaison between primary and 
secondary care for identifying people at 
clinical high risk of psychosis and with FEP. 
This study found that the high intensity 
For people with early signs of psychosis, 
it is cost-effective to use intensive 
intervention to improve liaison between 
primary and secondary care, compared 
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Target population Number of 
studies 
Countries Study quality Summary of results  Conclusion 
intervention dominates practice as usual and 
low-intensity intervention.  
to less-intensive intervention or no 
intervention.  
Abbreviation: 
DALY: disability-adjusted life year; LAI: long acting injection; QALY: quality-adjusted life year; WTP: willingness-to-pay.  
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3.4.1 Conclusions for antipsychotics  
Owing to considerable variability in the number and type of antipsychotics assessed, as well as inconsistent 
conclusions reported by different studies, it was not possible to identify the most cost-effective antipsychotic for 
the following patient groups: schizophrenia patients in an acute episode, in remission, or with unspecified 
psychotic status; schizophrenia patients who have a history of non-adherence; and patients with TRS. For 
schizophrenia patients who are experiencing adverse events of typical antipsychotics, one study found oral 
risperidone to be cost-effective compared to oral olanzapine or oral typical antipsychotics [53]. For patients with 
negative symptoms of schizophrenia, one study found oral cariprazine is more cost-effective than oral 
risperidone [81]. 
 
Of the 57 identified antipsychotic models, 45 reported potential conflicts of interest (the study was funded by, or 
affiliated with, commercial companies). All 45 studies reported positive findings for the antipsychotic 
manufactured by the sponsoring commercial company, which indicates that the conclusions of these 45 models 
might have been influenced by conflicts of interest. Focusing on the 12 studies which did not report potential 
conflicts of interest, the relative cost-effectiveness of the two most frequently assessed antipsychotics – oral 
olanzapine and oral risperidone – was explored in order to assess the consistency of conclusions across studies. 
The results, reported in Table 3, show that for all three patient groups for whom data were available, the studies 
with no conflicts of interest reported inconsistent conclusions. For example, for studies which focused on 
schizophrenia patients in remission, two studies found oral risperidone was cost-effective compared to oral 
olanzapine [1, 31], while three studies found oral olanzapine was cost-effective compared to oral risperidone 
[42, 47, 50].  
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Table 3 Consistency of cost-effectiveness conclusions reported by studies of antipsychotics with no 
conflicts of interest 
Conclusion Number of studies 
support the conclusion 
References 
General adult schizophrenia patients (psychotic status unspecified) 
Oral risperidone is cost-effective compared to oral olanzapine 1 [53] 
Oral olanzapine is cost-effective compared to oral risperidone 1 [75] 
Schizophrenia patients in an acute episode   
Oral risperidone is cost-effective compared to oral olanzapine 1 [40] 
Oral olanzapine is cost-effective compared to oral risperidone 1 [37] 
Schizophrenia patients in remission   
Oral risperidone is cost-effective compared to oral olanzapine 2 [1, 31] 
Oral olanzapine is cost-effective compared to oral risperidone 3 [42, 47, 50] 
  
3.4.2 Conclusions for non-pharmacological interventions 
Five models compared the cost-effectiveness of antipsychotic medication alone with antipsychotic medication 
plus psychosocial interventions [26-30]. All of these studies concluded that antipsychotic medication plus 
psychosocial interventions was cost-effective compared to antipsychotic medication alone. For the remaining 
non-pharmacological interventions, each was only assessed by one model. The interventions found to be cost-
effective by these models, and the comparators, are as follows: 
• a Medicare scheme which covers the cost of generic antipsychotics, compared to no coverage [19]; 
• clozapine for patients with TRS who respond to, and who can tolerate clozapine, compared to typical  
antipsychotics and ECT; and ECT for patients with TRS who have not responded to, or who cannot 
tolerate, clozapine, compared to typical antipsychotics  [20]; 
• a stratified test with 60% sensitivity and 60% specificity for identifying patients who would respond to 
a second-line non-clozapine antipsychotic after failing a first-line non-clozapine antipsychotic, 
compared to no stratified test [23]; 
• a stratified test with 100% accuracy to inform the starting dose of risperidone for patients with first 
episode psychosis (FEP), compared to no stratified test [22]; 
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• human leukocyte antigen genotyping for identifying patients with TRS who are likely to develop 
clozapine-induced agranulocytosis, compared to no test [24]; 
• no monitoring for patients with TRS on clozapine, compared to monitoring [25]; 
• antipsychotic plus psychosocial interventions for schizophrenia patients, compared to antipsychotic 
alone [26-30];  
• CBT for patients with ultra-high risk of developing psychosis or with FEP, compared to no CBT [17]; 
• A programme to improve patients’ access to psychological therapies, compared to current practice 
[18];  
• supported employment programme for patients with psychosis or schizophrenia actively seeking 
employment, compared to current practice [1]; 
• an intensive intervention to improve liaison between primary and secondary care for people with early 
signs of psychosis, compared to a less-intensive intervention or no intervention [15]. 
 
4 Discussion  
4.1 Summary of findings   
This review of economic models of interventions for schizophrenia found the quality of existing models to be 
generally low. Common reasons for low-quality included use of a time-horizon which was not sufficiently long, 
failure to capture the health and cost impact of adverse events of the interventions under assessment, and 
potential conflicts of interest which may have biased the results of the analyses. 
 
78% of existing models assessed the cost-effectiveness of antipsychotics. However, it was not possible to 
identify the most cost-effective antipsychotic for the majority of schizophrenia patients due to considerable 
variation in terms of the number and type of antipsychotics assessed and inconsistent conclusions reported by 
different studies. Inconsistent findings were a problem for models with conflicts of interest and those where no 
conflict of interest was identified, which suggests that the variation in results cannot be explained solely by 
conflicts of interest, but are also likely to be related to differences in choice of treatment options and variances 
in methods, such as model structure, type of adverse events considered, source of input data and methods of 
evidence synthesis. The review found very limited or even no economic evidence concerning the prevention, 
case identification, assessment and diagnosis of psychosis and schizophrenia, as well as non-pharmacological 




4.2 Recommendations for future research  
4.2.1 Interventions prioritised for future modelling  
A number of interventions for schizophrenia have been recommended in the NICE schizophrenia guideline [1], 
but have not been formally assessed for cost-effectiveness within a model-based economic evaluation 
framework. These include: (i) assessment and diagnosis for people with possible psychosis; (ii) interventions to 
manage challenging behaviour in people with psychosis/schizophrenia; (iii) intervention to promote physical 
health in people with psychosis/schizophrenia; (iv) peer support or self-management interventions to improve 
symptoms and functioning for people with psychosis/schizophrenia; and (v) teams and service-level 
interventions. It is recommended that the above interventions should be prioritised for future economic models.  
 
4.2.2 Improvements to the consistency and quality of economic analyses in schizophrenia 
One option for improving the consistency and quality of economic analyses in schizophrenia would involve the 
development of an agreed ‘generic’ model structure [82], populated using input data obtained from high quality 
evidence, which would allow for the consistent economic evaluation of new and existing treatment options as 
and when such analyses are required (e.g. when a new drug comes to market). Provided the basis of the model 
(e.g. its structure and the evidence used to inform it) can be agreed, the development of a generic schizophrenia 
model would remove the possibility of producing inconsistent results and improve model quality. Development 
of a registry of economic models by disease areas is a potential method for promoting use of generic modelling 
approach [83].  
 
As an extension of generic models, Tappenden et al. have proposed the development of Whole Disease Models 
(WDMs) – these are generic models which, in principle, allow for the consistent economic analysis of any 
individual or combination of options at any point in the disease and treatment pathway [84]. This “whole 
system” approach would provide a single platform for the economic evaluation of all key interventions for 
schizophrenia based on a common set of assumptions and input data across the whole care pathway. Whilst this 
type of modelling approach represents a significant undertaking in terms of model development time and 
resource, it would provide a means of addressing the significant gaps identified within this review relating to the 
inconsistent and/or absent economic evidence for current treatments for schizophrenia. In addition, it may be 
particularly valuable in capturing interactions between interventions given at different points of the pathway, for 
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example, interventions which reduce a patient’s duration of untreated psychosis earlier in the pathway are likely 
to impact upon the cost-effectiveness of other treatments later on in the pathway.  
 
4.3 Strengths & Limitations  
4.3.1 Strengths  
Whilst a number of systematic reviews have been identified that assess economic studies for schizophrenia, 
most of them focused on cost-effectiveness of antipsychotics and ignored other non-pharmacological 
interventions [1, 85-87]. Before our study, there is only one review (Németh et al.[88]) which includes all 
model-based economic evaluation for schizophrenia regardless of which intervention was assessed. However, 
Németh et al. only searched one electronic database (MEDLINE); in addition, it focused on the methods used by 
published models such as utility mapping algorithms, without reporting conclusions of the identified models. To 
our knowledge, our study presents the first systematic review which summarises the cost-effectiveness evidence 
reported by existing model-based economic analyses which covers the entire schizophrenia care pathway, 
including any intervention for the prevention, detection, diagnosis, treatment and follow-up of schizophrenia. 
The information reported by this systematic review can be used to help researchers, commissioners or other 
stakeholders to rapidly locate relevant economic evidence that they are interested in, critically appraise existing 
model-based economic analyses, and make resource allocation decisions based on current model-based 
economic analyses. Recommendations for future research can be used to fill the evidence gap and improve the 
applicability and quality of future models for schizophrenia.  
 
4.3.2 Limitations 
This review is subject to two main limitations. Firstly, this review only included model-based economic 
evaluations. Economic evaluations based on other analytic frameworks, such as clinical trials, cohort studies and 
database studies, which represent a significant proportion of economic evidence, were excluded from this 
review. Economic analyses undertaken alongside clinical trials without extrapolation or the use of external 
evidence can also be a useful source of economic evidence; however, they do not always provide a sufficient 
basis for decision-making. For example, a single trial might not compare all the available options, provide 
evidence on all relevant inputs, or be conducted over a long enough period of time to capture differences in 
important economic or clinical outcomes. Therefore, a review of model-based economic evaluations was 
considered to be most relevant for decision-makers who are interested in resource allocation decisions across the 
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entire schizophrenia pathway. Secondly, this review only included models published after 2005. This is because 
studies published before that time were deemed to have limited relevance to current practice due to the rapidly 
changing nature of treatments, health services and methods of economic evaluation.  
 
5 Conclusion  
This review highlights a lack of models for non-pharmacological interventions for schizophrenia, and 
limitations of existing models, including low quality and inconsistency in conclusions. A consistent basis for the 
model structure, use of evidence and assumptions in health economic models is required, in order to improve the 
consistency and quality of future health economic models for the economic evaluation of interventions for 
schizophrenia. This consistency could be applied using ‘generic’ models, which might include a de novo WDM.  
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